Takeda Pharmaceutical (NYSE:TAK) Insider Sells 6,774 Shares

Takeda Pharmaceutical Co. (NYSE:TAK) insider Nicola Deidre Petal Greenway sold 6,774 shares of Takeda Pharmaceutical stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $17.10, for a total transaction of $115,835.40. Following the sale, the insider owned 53,029 shares of the company’s stock, valued at approximately $906,795.90. This trade represents a 11.33% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Takeda Pharmaceutical Trading Down 0.3%

Shares of NYSE:TAK traded down $0.06 during trading on Wednesday, reaching $17.42. The stock had a trading volume of 2,004,364 shares, compared to its average volume of 4,402,927. The company has a quick ratio of 0.62, a current ratio of 1.14 and a debt-to-equity ratio of 0.58. The stock has a market cap of $55.82 billion, a P/E ratio of 51.24 and a beta of -0.08. The business has a fifty day moving average price of $16.49 and a 200-day moving average price of $17.13. Takeda Pharmaceutical Co. has a fifty-two week low of $12.99 and a fifty-two week high of $18.90.

Takeda Pharmaceutical (NYSE:TAK) last announced its earnings results on Tuesday, March 31st. The company reported $0.56 earnings per share (EPS) for the quarter. The firm had revenue of $6.90 billion for the quarter. Takeda Pharmaceutical had a net margin of 3.80% and a return on equity of 10.95%. As a group, analysts anticipate that Takeda Pharmaceutical Co. will post 3.01 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Takeda Pharmaceutical

Institutional investors have recently added to or reduced their stakes in the company. Renaissance Technologies LLC raised its holdings in shares of Takeda Pharmaceutical by 14.2% in the 1st quarter. Renaissance Technologies LLC now owns 2,989,100 shares of the company’s stock worth $55,358,000 after purchasing an additional 370,800 shares during the period. China Universal Asset Management Co. Ltd. acquired a new stake in Takeda Pharmaceutical during the 4th quarter worth approximately $998,000. Quantinno Capital Management LP raised its holdings in Takeda Pharmaceutical by 20.6% in the first quarter. Quantinno Capital Management LP now owns 1,289,326 shares of the company’s stock valued at $23,878,000 after buying an additional 219,999 shares during the period. Sivia Capital Partners LLC acquired a new position in Takeda Pharmaceutical during the second quarter valued at approximately $351,000. Finally, Bleakley Financial Group LLC lifted its position in Takeda Pharmaceutical by 19.0% during the first quarter. Bleakley Financial Group LLC now owns 431,602 shares of the company’s stock valued at $7,993,000 after buying an additional 68,844 shares in the last quarter. Hedge funds and other institutional investors own 9.17% of the company’s stock.

Analysts Set New Price Targets

TAK has been the subject of a number of recent analyst reports. Wall Street Zen raised Takeda Pharmaceutical from a “hold” rating to a “buy” rating in a research report on Saturday, July 18th. Weiss Ratings downgraded Takeda Pharmaceutical from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Thursday, July 30th. Finally, Zacks Research raised Takeda Pharmaceutical from a “strong sell” rating to a “hold” rating in a research note on Tuesday, August 4th. Two equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Hold”.

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited (NYSE: TAK) is a Tokyo-based, multinational biopharmaceutical company with roots dating back to 1781. The company researches, develops, manufactures and commercializes pharmaceutical and biopharmaceutical products for patients worldwide. Takeda is publicly listed and operates as a fully integrated R&D-driven healthcare company focused on delivering specialty medicines and therapies across a range of therapeutic areas.

Takeda’s main business activities encompass discovery and development of prescription medicines, clinical development and regulatory affairs, manufacturing of small molecules and biologics, and global commercial operations.